Recent Updates
Recently added Catalysts

ImageneBio, Inc.

IMAFDA catalysts, PDUFA dates & pipeline intelligence
$3.98
▲ +0.17 · +4.46%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full IMA financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $3.0052W HIGH $7.89
Volume
27.54 K
Value Traded
109.28 K
Short % Float
0.58%
Days to Cover
4.0
+15.36%Week
-3.63%1 Month
-29.06%3 Month
-27.9%6 Month
-99.8%5 Year
-99.83%All Time

Cash Data

Unlock IMA cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
49.58 M
EPS (TTM)
-3.66
P/E Ratio
-
Ent. Value
-77.02 M
Total Shares
12.46 M
Float Shares
7.96 M
Insiders
36.07%
Institutions
35.33%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2b topline data readout
IMG-007 (non-depleting anti-OX40 monoclonal antibody)
moderate-to-severe atopic dermatitis
Phase 2bBiologicsDermatology
Unlock every IMA catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

IMA Catalyst Timeline

Dated clinical, regulatory and corporate events for ImageneBio, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for ImageneBio, Inc.

61Total events
8Upcoming
13Tier-1 (high impact)
2023 to 2028Coverage

Upcoming catalysts 2

T1Topline Readout
Subscribe to view catalyst details
IMG-007
T1Topline Readout
Subscribe to view catalyst details
IMG-007

Event history 44

●Quarterly UpdateCorporate
ImageneBio reports third quarter 2026 financial results
●Equity OfferingCorporate
Inducement awards of 90,775 RSUs and 32,725 NSOs granted to three new employees
●Quarterly UpdateCorporate
Second quarter 2026 financial results reported
▲Safety Data UpdateIMG-007Clinical Data
No cases of Kaposi sarcoma observed as of July 31, 2026
▲DSMB ReviewIMG-007Trial
IDMC recommended study proceed with no changes
atopic dermatitissource ↗
◆Management ChangeCorporate
Appointment of Matt Robbins as General Counsel
●Management ChangeCorporate
Appointed Matt Robbins as General Counsel
◆Oral PresentationPresentation
CEO presentation at Jefferies Global Healthcare Conference
◆Oral PresentationIMG-007Presentation
Oral presentation of preclinical data at SID Meeting
inflammatory and autoimmune diseasesource ↗
●Quarterly UpdateCorporate
Reported first quarter 2026 financial results
Unlock the full IMA catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How IMA actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-09-30Olevaprubart (IMG-007) Phase 1b/2a data readout Phase 1b/2a
Unlock all IMA historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 49%
Micro Cap
(rank 355 of 723)
Percentile Rank
Showing 4 of 4 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
IMG-007 BiologicsNCT07734415Atopic DermatitisPhase 2 ENROLLING BY_INVITATION 805Mar 1, 2028
IMG-007 BiologicsCompletedNCT06060977Alopecia Areata (AA)Phase 1/2 COMPLETED 29Jan 14, 2025
SAD IMG-004 Small MoleculesCompletedNCT05349097UndisclosedPhase 1 COMPLETED 72May 2, 2024
IK-175 Small MoleculesCompletedNCT04200963Urothelial CarcinomaPhase 1 COMPLETED 78Jul 18, 2023
Unlock the IMA pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every IMA program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
IK-930 epithelioid hemangioendotheliomaPhase 12023-11-09patients treated: 26; tumor shrinkage: encouraging signs; treatment related proteinuria: 3 out of 26 patients; proteinuria grade: grade 1-2Read MoreIkena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results Favorable safety profile in dose escalation shown to date; selectiRead More
Scroll for more · summaries link to the source press release
Unlock every IMA trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock IMA insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Yarema KristinDirector, Officer (Chief Executive Officer)Option 38,376 123,776 held$0.00 07/25/2026
Unlock the full IMA insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
BVF INC/IL 0.2 % 5.08 M 1.11 M
Unlock every fund holding IMA
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in IMA
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see IMA ownership
Insider and institutional ownership, quarter by quarter.

IMA Short Interest

Shares sold short, counted twice a month.

0.58%
Short % of Float
of tradable shares sold short
46.0K
Shares Sold Short
-25.1% vs prior count
4.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
11.6K
Avg Daily Volume
the average used for days to cover
Unlock IMA short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock IMA option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live IMA option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock IMA options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How IMA ranks across every disease it competes in

Competitive Position is a premium feature
See how IMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

IMA News

IMA
Nov 9, 2026
IMAGeneral

ImageneBio Reports Third Quarter 2026 Financial Results

ImageneBio reported its Q3 2026 financial results, highlighting progress in the Phase 2b ADAPTIVE trial for olevaprubart, an anti-OX40 receptor antagonist. The company anticipates topline data in Q4 2027 and plans to initiate a Phase 2 study in alopecia areata by year-end. The financial position remains strong with $126.6 million in cash.

Read more →
IMA
Oct 2, 2026
IMAGeneral

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImageneBio, Inc. announced the granting of inducement awards to three new employees, consisting of 90,775 restricted stock units and 32,725 non-qualified stock options. These awards are part of the company's strategy to attract talent under Nasdaq Listing Rule 5635(c)(4). Additionally, Imagene is advancing its clinical trials for its lead therapeutic candidate, olevaprubart, targeting immunological diseases.

Read more →
IMA
Sep 8, 2026
IMAConferences/Events

ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York

ImageneBio, Inc. announced that CEO Kristin Yarema will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company is engaged in developing therapeutics for immunological diseases and is currently conducting a Phase 2b clinical trial for its drug, olevaprubart, in atopic dermatitis. This event highlights ImageneBio's ongoing commitment to advancing its clinical programs.

Read more →
IMA
Aug 5, 2026
IMAGeneral

ImageneBio Reports Second Quarter 2026 Financial Results

ImageneBio reported its Q2 2026 financial results, highlighting progress in the Phase 2b ADAPTIVE trial of its drug Olevaprubart for atopic dermatitis. The company has opened a long-term extension study and plans to initiate a Phase 2 trial for alopecia areata. Despite a net loss of $10.2 million, Imagene maintains a robust cash position of $136.2 million, sufficient to fund operations into 2028.

Read more →
IMA
Jul 7, 2026
IMAGeneral

ImageneBio Appoints Matt Robbins as General Counsel

ImageneBio has appointed Matt Robbins as General Counsel, effective July 7, 2026. Robbins, an experienced attorney in life sciences, will oversee legal and compliance functions as the company advances its lead candidate, IMG-007. ImageneBio is excited about its growth phase and upcoming clinical milestones in treating atopic dermatitis and alopecia areata.

Read more →
IMA
May 27, 2026
IMAConferences/Events

ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York

ImageneBio, Inc. announced its participation in the Jefferies Global Healthcare Conference on June 4, 2026. CEO Kristin Yarema will present at the event, which will also include one-on-one meetings with management. The company is focused on developing therapies for immunological and autoimmune diseases, with ongoing clinical trials for its product IMG-007.

Read more →
IMA
May 7, 2026
IMAPhases

ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update

ImageneBio reported its Q1 2026 financial results and provided updates on its lead program, IMG-007, which is advancing into a Phase 2 clinical trial for alopecia areata. The company secured $30 million in financing, extending its cash runway into early 2028. IMG-007 is notable for its non-T cell-depleting mechanism and is currently being evaluated in a Phase 2b trial for atopic dermatitis with topline data expected in late 2027.

Read more →
IMA
Apr 13, 2026
IMAGeneral
▲ +23.4%on this news

ImageneBio Announces $30 Million Private Placement

ImageneBio has announced a $30 million private placement with institutional investors to fund the development of its drug IMG-007 for alopecia areata and atopic dermatitis. The company is optimistic about the progress of its Phase 2b ADAPTIVE trial and the potential of IMG-007 as a disease-modifying treatment. The placement involves pre-funded warrants and is led by Coastlands Capital.

Read more →
IMA
Mar 10, 2026
IMAGeneral

ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

ImageneBio, Inc. reported its financial results for Q4 and full year 2025, highlighting the promising clinical progress of its lead candidate, IMG-007, an OX40 antagonist. The company has observed no significant tolerability issues, differentiating it from its competitors. With a robust financial position, bolstered by recent funding and a merger, it plans to advance its Phase 2b ADAPTIVE trial in atopic dermatitis, while remaining aware of competition and potential safety concerns in the field. An upcoming presentation at the SID Meeting will showcase additional preclinical data on IMG-007's innovative profile.

Read more →
IMA
Feb 26, 2026
IMAConferences/Events

ImageneBio to Participate in Leerink Global Healthcare Conference

ImageneBio, Inc. will participate in the 2026 Leerink Global Healthcare Conference from March 8-11 in Miami, Florida. The company will engage in a fireside chat and hold one-on-one meetings to discuss its clinical-stage programs, particularly IMG-007, which is in Phase 2b trials for atopic dermatitis. This involvement highlights the company's commitment to advancing its therapeutic developments.

Read more →
IMA
Feb 10, 2026
IMAGeneral

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

ImageneBio has appointed Dr. Ben Porter-Brown as Chief Medical Officer to lead its clinical organization and oversee the Phase 2b ADAPTIVE trial for atopic dermatitis. With over 20 years of experience in autoimmune and inflammatory diseases, Dr. Porter-Brown aims to enhance the company's clinical capabilities and expand its trial sites internationally. His expertise in OX40 signaling inhibitors is expected to significantly benefit the development of Imagene's drug IMG-007.

Read more →
IMA
Nov 19, 2025
IMAGeneral

ImageneBio Corporate Overview Fourth Quarter 2025 Disclaimer and forward-looking statements This investor presentation and any accompanying oral commentary have been prepared by ImageneBio, Inc. (the Company) for informa

ImageneBio, Inc. presented an overview of its corporate status and future prospects, highlighting its immunology innovations, particularly IMG-007, aimed at treating atopic dermatitis. The presentation emphasized the current unmet needs in the atopic dermatitis market, where existing treatments fall short for a significant portion of patients. ImageneBio has a well-established funding runway anticipated to extend until the end of 2027, supporting their ongoing Phase 2b clinical studies. However, risks surrounding the clinical development process and dependency on external partners were also noted.

Read more →
IMA
Nov 12, 2025
IMAPhases

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

ImageneBio reported its third quarter 2025 financial results, revealing a cash balance of $142.6 million following a reverse merger and concurrent financing. The company provided an update on the ongoing Phase 2b ADAPTIVE study of its anti-OX40 monoclonal antibody, IMG-007, focusing on atopic dermatitis, highlighting strong patient enrollment and planned protocol amendments to optimize the trial. Leadership changes and upcoming data presentations at a key summit further indicate an active progression in their clinical programs. However, the firm also noted a substantial net loss and ongoing risks linked to clinical and regulatory developments.

Read more →
IMA
Aug 1, 2025
IMAGeneral

I MAGENE B IO , I NC . 2025 E QUITY I NDUCEMENT P LAN A DOPTED BY THE B OARD OF D IRECTORS : J ULY 28, 2025 1. G ENERAL . (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of El

I Magene Bio, Inc. has announced the adoption of a 2025 equity inducement plan by its Board of Directors. The plan is designed to attract and retain eligible employees by providing them with incentives linked to the company's stock performance. The Board can grant nonstatutory stock options and restricted stock units under specific guidelines dictated by Nasdaq rules. The plan includes provisions on share reserves and eligibility, aiming to promote employee engagement and commitment to the company's success.

Read more →
IMA
Jul 29, 2025
IMAGeneral
▼ -7.1%on this newsshared move

Corporate Overview July 2025 Disclaimer This presentation contains "forward-looking statements" under the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. ImageneBio, Inc.'

ImageneBio, Inc. has outlined its forward-looking statements regarding the development of its lead program, IMG-007, aimed at treating atopic dermatitis (AD) and alopecia areata (AA). The company has reported promising initial results from clinical trials, showing rapid and sustained improvements in patient scores for AD. However, the presentation highlights significant risks, including the uncertainties involved in clinical trials and the overall financial health of the company. The completion of a merger in July 2025 is expected to enhance Imagene's strategic position in the biopharmaceutical industry.

Read more →
IMA
Jul 28, 2025
IMAGeneral

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private

Inmagene Biopharmaceuticals has completed its merger with Ikena Oncology, forming a new entity named ImageneBio, Inc., which will begin trading on Nasdaq under the ticker symbol IMA on July 28, 2025. The merger is accompanied by a $75 million private placement aimed at advancing the clinical development of IMG-007, a monoclonal antibody targeting OX40 for treating immunological diseases. ImageneBio is set to continue its Phase 2b trial for IMG-007 in moderate-to-severe atopic dermatitis, with topline results expected in late 2026.

Read more →
IMA
Jul 15, 2025
IMAGeneral

Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals Combined Company to Trade on Nasdaq Under Ticker IMA

Ikena Oncology has announced that stockholders have approved the merger with Inmagene Biopharmaceuticals, enabling the combined company to list on Nasdaq under the ticker IMA. Additionally, a reverse stock split of 1-for-12 has been confirmed, reducing the total number of shares. The merger's completion and the new trading arrangements are expected to initiate around the end of July. Ikena is known for its development of therapies targeting cancer, while Inmagene has focused on therapeutics for immunological and inflammatory diseases.

Read more →
IMA
Jul 11, 2025
IMAGeneral

Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote FOR Proposed Merger

Ikena Oncology has announced that Institutional Shareholder Services and Glass Lewis have recommended stockholders approve the proposed merger with Inmagene Biopharmaceuticals. This recommendation is crucial as Ikena's Annual Meeting is set for July 15, 2025, where stockholders will vote on this and other proposals. The merger aims to leverage Inmagene's lead candidate, IMG-007, which has shown promise in treating atopic dermatitis. The merger's approval could significantly impact Ikena's market position and growth potential in immunological and inflammatory diseases.

Read more →

About ImageneBio, Inc.

San Diego, CA 18 employees imagenebio.com
Headquarters12526 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130
BIOPHARMAWATCH ELITE
Trade the next IMA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime